Marc Humbert has current or past relationships with drug companies including Actelion, AstraZeneca, Bayer, Gilead, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and Teva. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
DEPUTY CHIEF EDITOR
Robert Bals has received grants from the German Research Ministry, Deutsche Forschungsgemeinschaft, Mukoviszidose eV and Sander-Stiftung, and received personal fees from and appeared on advisory boards for GSK, AstraZeneca and Boehringer Ingelheim.
Pascal Chanez has received fees for clinical trials from Boehringer Ingelheim. He has also received grants and personal fees for consultancy advisory board involvement and lecture fees from Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough. He has also received personal fees for consultancy advisory board involvement and lecture fees from MSD and AMU.
Vincent Cottin has received personal fees for consultancy, lecture fees and reimbursement for attending meetings from Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, Gilead, GSK, Intermune, MSD, Novartis, Pfizer, Roche and Sanofi. He has also received grants from Actelion, Boehringer Ingelheim, GSK, Pfizer and Roche, and personal fees from Boehringer Ingelheim for the development of educational presentations.
Martin Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic and Alkermes; grants from Actelion, Respivert and Synairgen; and personal fees from AstraZeneca and Genoa.
Ian Pavord has received speaker’s honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis and GSK, and a payment for organising an educational event from AZ; has received honoraria for attending advisory panels with Almirall, Genentech, Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, MSD, Schering-Plough, Novartis, Dey, Napp and Respivert; and has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca and Napp.
Luca Richeldi has received grants and personal fees from for acting as a member of an advisory board from InterMune, personal fees for acting as a member of an advisory board from Medimmune, Roche and Takeda, personal fees for consultancy work from Biogen-Idec, Sanofi-Aventis and ImmuneWorks, personal fees for speaking from Shionogi, and personal fees for acting as a steering committee member from Boehringer Ingelheim.
Joan B. Soriano received pharmaceutical company grants 2014 to 2016 from Linde via Hospital Universitario de La Princesa; received consulting fees 2014 to 2015 from ERS and 2015 to 2016 from SEPAR; and participated in speaking activities, advisory committees and consultancies during the period 2015 to 2016 sponsored by: Air Liquide, Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, ERS, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, SEPAR and Takeda.